Aileron Therapeutics is a biopharmaceutical company leading the development of a new class of drugs called Stapled Peptides. Stapled Peptides are a breakthrough solution to address thousands of therapeutically important yet currently undruggable targets. Stapled Peptides have demonstrated their unique ability to penetrate cells throughout the body and modulate protein-protein interactions, critical control points for most human diseases. Aileron is building a robust pipeline of therapeutics for the treatment of cancer, infectious disease, metabolic disease and immune/inflammatory diseases.

Spotlight On...

alt

February 14, 2014
Aileron Therapeutics to Present at 2014 Leerink Global Healthcare Conference
More

November 18, 2013
Aileron Therapeutics Secures $30 Million in New Financing
More

August 15, 2013
Aileron Therapeutics Publishes Data Demonstrating ATSP-7041 as First-in-class p53 Pathway Re-activator for the Treatment of Solid and Hematologic Cancers
More

May 7, 2013
Aileron Therapeutics Successfully Completes First-Ever Stapled Peptide Clinical Trial
More

View All

Featured Publications

Aileron and p53 pathway re-activator ATSP-7041 featured in Nature Reviews Drug Discovery Research Highlights: "Stapled peptide reactivates p53." 
More


Preclinical results demonstrating ATSP-7041 as first-in-class p53 pathway re-activator published in PNAS: "Stapled α−helical peptide drug development: A potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy." 
More


Aileron and Stapled Peptides featured in SciBx collection "Macrocycles and Constrained Peptides."
More


Key insights on Stapled Peptides targeting p53 pathway in cancer published in ACS Chemical Biology letter titled, "Stapled Peptides with Improved Potency and Specificity That Activate p53." 
More

View All